A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

BACKGROUND: Mazindol is under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD) because of its alertness-enhancing properties. A novel controlled-release (CR) formulation of mazindol was developed to allow once-daily dosing. OBJECTIVE: The aim of this study was to ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Wigal, Tim L., Newcorn, Jeffrey H., Handal, Nelson, Wigal, Sharon B., Mulligan, Ioulietta, Schmith, Virginia, Konofal, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889769/
https://www.ncbi.nlm.nih.gov/pubmed/29557078
http://dx.doi.org/10.1007/s40263-018-0503-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889769/
https://www.ncbi.nlm.nih.gov/pubmed/29557078
http://dx.doi.org/10.1007/s40263-018-0503-y

Ejemplares similares